ORIGINAL ARTICLEProton Pump Inhibitor Therapy for Peptic Ulcer Bleeding: Cochrane Collaboration Meta-analysis of Randomized Controlled Trials
Section snippets
MATERIAL AND METHODS
We included trials that compared intravenous or oral PPIs with placebo or a histamine2-receptor antagonist (H2RA) in patients with ulcer bleeding. All trials had to confirm endoscopically the diagnosis of active or recent bleeding from peptic ulcer, use a concurrent control group, apply concomitant therapy equally to both intervention arms, and report 1 or more of the following: mortality, rebleeding, and surgical intervention.
Our primary outcome measure was mortality from any cause within 30
RESULTS
Our initial search identified 181 articles; reference lists from these articles and conference proceedings identified an additional 16 articles (Figure 1). We identified no additional trials by searching online registers of controlled trials or by contacting experts in the field or pharmaceutical companies that market PPIs. After reviewing the abstracts of these articles, we excluded 143 as irrelevant and retrieved the full text for the remaining 54. Of these, 30 did not meet eligibility
DISCUSSION
These results extend and update our previous analyses.1, 2 Treatment with PPIs consistently reduces the rate of rebleeding after an episode of ulcer bleeding and also reduces the requirement for surgical treatment. New findings that add to existing knowledge are that PPI treatment reduces all-cause mortality among patients with major endoscopic stigmas and reduces the requirement for repeated endoscopic hemostatic treatment. Trials conducted in Asia demonstrate some important differences in
CONCLUSIONS
Treatment with PPIs plays an important part in the management of patients with ulcer bleeding. It reduces rebleeding and the requirements for surgical intervention and additional endoscopic hemostatic treatment. When appropriately combined with endoscopic hemostatic treatment, PPI treatment also improves mortality among patients with the highest-risk endoscopic findings.
Acknowledgments
We thank Iris Gordon, MSc, trial search coordinator, Cochrane Collaboration, Upper Gastrointestinal and Pancreatic Diseases Group, University of Leeds, for her help with the literature search.
REFERENCES (42)
- et al.
Acute upper gastrointestinal hemorrhage: preliminary report of a randomized controlled trial comparing intravenous administration of ranitidine and omeprazole [abstract]
Gastroenterology
(1995) - et al.
Omeprazole as adjuvant therapy to endoscopic combination injection sclerotherapy for treating bleeding peptic ulcer
Am J Med
(2001) - et al.
Effects of acid and pepsin on blood coagulation and platelet aggregation: a possible contributor to prolonged gastroduodenal mucosal hemorrhage
Gastroenterology
(1978) - et al.
Proton pump inhibitor treatment for acute peptic ulcer bleeding
Cochrane Database Syst Rev
(2004) - et al.
Systematic review and meta-analysis of proton pump inhibitor therapy in peptic ulcer bleeding
BMJ
(2005 Mar 12) - et al.
Proton pump inhibitor treatment for acute peptic ulcer bleeding
Cochrane Database Syst Rev
(2006) - et al.
Bias in meta-analysis detected by a simple, graphical test
BMJ
(1997) - et al.
Comparison of intravenous pantoprazole with intravenous ranitidine in peptic ulcer bleeding [abstract]
Gut
(1999) - et al.
Comparison of intravenous pantoprazole with intravenous ranitidine in prevention of rebleeding from gastroduodenal ulcers [abstract]
Gut
(2001)
Prevention of peptic ulcer rebleeding using continuous infusion of pantoparzole vs ranitidine: a multicenter, multinational, randomized, double-blind, parallel-group comparison [abstract]
Gastroenterology
Lower rebleeding rates in high risk patients treated with IV pantoprazole than IV ranitidine after endoscopic hemostasis in a randomised controlled US study [abstract]
Am J Gastroenterol
Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled study
Digestion
Omeprazole versus placebo for acute upper gastrointestinal bleeding: randomised double blind controlled study
BMJ
Lansoprazole versus ranitidine dans la prévention des récidives précoces des hémorragies digestives ulcéreuses gastro-duodénales
Gastroenterol Clin Biol
Tratamiento de la hemorragia digestive alta de origen péptico: ranitidina intravenosa versus omeprazol intravenoso
Rev Esp Enferm Dig
Effect of parenteral omeprazole and ranitidine on gastric pH and the outcome of bleeding peptic ulcer
J Clin Gastroenterol
Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study
Endoscopy
Omeprazole versus ranitidine intraveineux dans le traitement de l'ulcere duodenal hemorragique: une etude randomisee prospective
Ann Chir
Continuous intravenous infusion of omeprazole in elderly patients with peptic ulcer bleeding: results of a placebo-controlled multicenter study
Scand J Gastroenterol
A comparison of omeprazole and placebo for bleeding peptic ulcer
N Engl J Med
Cited by (131)
Nonvariceal Upper Gastrointestinal Bleeding
2019, Clinical Gastrointestinal EndoscopyGastrointestinal Bleeding
2016, Emergency Medicine Clinics of North AmericaCitation Excerpt :When given before endoscopy, PPIs have been shown to reduce stigmata of recent hemorrhage seen during endoscopy and the need for endoscopic intervention.40,67 For ulcer-related UGIB, the use of PPIs is associated with decreased rates of rebleeding and need for surgery.68 As the exact location of an UGIB may not be clearly known before endoscopy, the emergency physician should consider giving a PPI to all patients with a suspected upper GI source.
Proton pump inhibitors for upper gastrointestinal bleeding
2019, Best Practice and Research: Clinical GastroenterologyResumption of Antiplatelet Therapy after Major Bleeding
2023, Thrombosis and HaemostasisInappropriateness of Proton Pump Inhibitors After Hospital Discharge Is Associated with Thirty-Day Hospital Readmission
2022, Digestive Diseases and Sciences
Data were presented in part at the 106th Annual Meeting of the American Gastroenterological Association, Chicago, Ill, May 18, 2005, and have been published in abstract form (Leontiadis et al. Gastroenterology. 2005; 128[suppl 2]:A-639. Abstract W1568). This report is based on a review3 published online in The Cochrane Library (www.thecochranelibrary.com), which will be updated regularly.
- 1
Dr Leontiadis receives grants to attend meetings from AstraZeneca Pharmaceuticals LP, Janssen-Cilag, GlaxoSmithKline, and Sanofi-Aventis. Dr Sharma receives speaking honoraria and research support from TAP Pharmaceutical Products Inc and is a consultant for Astra-Zeneca Pharmaceuticals LP. Dr Howden is a consultant for TAP Pharmaceutical Products Inc, Altana, Santarus, Inc, Schwarz Pharma, NEGMA-GILD, Allergan Inc, Novartis Consumer Health, Takeda Pharmaceuticals America, Inc, and Valeant Pharmaceuticals International; receives speaking honoraria from TAP Pharmaceutical Products Inc, Santarus, Inc, Takeda (Japan), Takeda (Austria), Abbott (Canada), Wyeth (US), Wyeth (Ireland), NEGMA-GILD, and AstraZeneca Pharmaceuticals LP, and receives research support from AstraZeneca Pharmaceuticals LP.